Infliximab
Trovati 15 articoli
- TNF-alpha antagonists associated with serious skin reactions
- Safety reviews of tumor necrosis factor-alpha ( TNF-a ) antagonists, Infliximab ( Remicade ), Etanercept ( Enbrel ), and Adalimumab ( Humira ) identified rare cases of serious skin reactions, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, associated with ... (Leggi Articolo)
- TNF-alpha inhibition linked to invasive fungal infections
- Tumor necrosis factor a ( TNF- alpha ) blockade has emerged as a useful therapy for collagen vascular diseases or graft-vs-host disease. Fungal infections complicating such therapy have been reported sporadically. Of the 281 cases of invasive fungal infections associated with TNF-alpha inhibit... (Leggi Articolo)
- Combined immunosuppression therapy better than conventional treatment in patients with Crohn's disease
- Combined immunosuppression therapy is more effective than conventional treatment using corticosteroids for inducing remission in and management of patients recently diagnosed with Crohn’s disease. Using intensive immunosuppressive therapy early in the course of the disease could result in better ... (Leggi Articolo)
- Autoimmune disease: cardiovascular benefits of anti-TNF therapy in rheumatoid arthritis
- A chronic autoimmune disease, rheumatoid arthritis is characterized by persistent inflammation of the synovial membrane and progressive joint destruction. Beyond loss of mobility, sufferers face a high risk of heart failure. An inflammatory cytokine known for contributing to the development of ... (Leggi Articolo)
- Several serious reactions linked to TNF-alpha inhibitors
- Tumour necrosis factor alpha ( TNF-alpha ) is a cellular protein produced by the immune system and is an important mediator of many diseases, including inflammatory arthritis and inflammatory bowel disease. Currently, three tumour necrosis factor alpha blocking agents are registered in Australi... (Leggi Articolo)
- Ulcerative colitis: Remicade appears effective
- Infliximab is the first biologic to show efficacy in two inflammatory bowel diseases ( IBD ), Crohn's Disease and ulcerative colitis. Results from two Phase III trials presented at Digestive Disease Week 2005 showed that, among patients with moderate to severe, active ulcerative colitis who ex... (Leggi Articolo)
- FDA approves Remicade for psoriatic arthritis
- FDA ( Food and Drug Administration ) has approved Remicade ( Infliximab ) to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis. Psoriatic arthritis affects approximately one million men and women in the U.S. and is often characterized by the complex sympt... (Leggi Articolo)
- Inflammatory bowel diseases: biological therapies
- IBD ( inflammatory bowel diseases ) is a term referring to several chronic diseases that cause inflammation of the intestines, including ulcerative colitis and Crohn's disease. Symptoms for both conditions are very similar and it is often difficult for physicians to differentiate between the t... (Leggi Articolo)
- Europe: Remicade for treatment of moderate to severe plaque psoriasis
- The European Commission has granted approval of Remicade ( Infliximab ), an anti-tumor necrosis factor alpha ( TNF-alpha ) blocker, for the treatment of moderate to severe plaque psoriasis. The new indication includes the treatment of moderate to severe plaque psoriasis in adults who failed to ... (Leggi Articolo)
- Sustained benefits of Remicade in patients with psoriatic arthritis
- In the IMPACT ( Infliximab Multinational Psoriatic Arthritis Controlled Trial ) study, 104 patients with active psoriatic arthritis who had failed at least one DMARD ( disease-modifying antirheumatic drug ) were enrolled at nine centers in the United States, Canada and Europe. Results demonstrat... (Leggi Articolo)
- Efficacy of Infliximab in patients with ulcerative colitis
- Patients with moderate-to-severe active ulcerative colitis treated with Infliximab ( Remicade ) at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. Data from two Phase III trials, ACT 1 and... (Leggi Articolo)
- Autoantibody formation in patients with rheumatoid arthritis treated with Infliximab
- Long-term use of anti-TNF-alpha agents can lead to the development of autoantibodies. Infliximab ( Remicade ) is a chimeric human-murine monoclonal antibody that inhibits TNF-alpha. Investigators from the Department of Rheumatology, University Hospital, Umea ( Sweden ) studied the prevalen... (Leggi Articolo)
- Rheumatoid arthritis, TNF-alpha blockers may cause skin diseases
- A prospective cohort study found that Tumour Necrosis Factor alpha ( TNF-alpha ) blocking agents, trigger skin conditions in 25% of patients with rheumatoid arthtitis. TNF-alpha blocking agents has had a remarkable effect on disease activity in a number of rheumatic diseases, including rheumat... (Leggi Articolo)
- Humira plus Methotrexate effective for long standing rheumatoid arthritis
- Combined treatment with Adalimumab ( Humira ) and Methotrexate is about five times more effective than Methotrexate alone in people with long-standing rheumatoid arthritis. In six randomized controlled trials, comprising 2381 people with at least 10 years of the disease, the authors report tha... (Leggi Articolo)
- TNF blockers linked to lymphoma risk
- The manufacturers of the drugs Humira ( Adalimumab ), Remicade ( Infliximab ) and Enbrel ( Etanercept ) have added new safety information to the labels for these products about malignancies. These three drugs are tumor necrosis factor ( TNF ) blocking agents, and they're used to treat rheumatoi... (Leggi Articolo)
